Samsung Biologics, a contract development and manufacturing organisation (CDMO), has launched S-HiCon, a new high-concentration formulation platform designed to enhance the development and manufacturing of high-dose drugs.
MinervaX, a Danish biotechnology company, has joined forces with contract development and manufacturing organisation (CDMO) Wacker Biotech for the manufacturing of MinervaX’s active protein ingredients for its Group B Streptococcus (GBS) vaccine.
Persist AI and Nivagen have joined forces to co-develop an advanced AI-driven manufacturing process for long-acting injectable (LAI) drugs.
Global healthcare holding company OSR Holdings has entered into a memorandum of understanding (MoU) with SillaJen, a South Korea-based biotechnology company with a pipeline of immuno-oncology drug candidates.
AGC Biologics has completed the facility expansion for its new plasmid DNA (pDNA) and messenger RNA (mRNA) production line at Heidelberg, Germany.
A biomanufacturing firm Wheeler Bio has launched a drug substance current good manufacturing practices (CGMP) facility in Oklahoma City, US.
Kincell Bio, a cell therapy contract development and manufacturing organisation (CDMO) spun out of Inceptor Bio, has launched with $36m investment with an aim to help early-stage innovators develop and manufacture cell therapies.
Contract development and manufacturing organisation (CDMO) Biovian has announced plans to make an investment worth more than $55m (€50m) to expand its manufacturing facility at Turku in Finland.
Samsung Biologics has announced a strategic collaboration with Pfizer for the long-term commercial manufacturing of the latter’s multi-product biosimilars portfolio.
Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) have announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended Kapruvia (difelikefalin) to treat chronic kidney disease (CKD)-associated pruritus.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.